NEOGENOMICS INC — Director's Dealing 2021

May 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-05-25

Reporting Person: SHOVLIN ROBERT J. (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-25	Common Stock	M	96167	$8.03	Acquired	249914	Direct
2021-05-25	Common Stock	M	16724	$19.60	Acquired	266638	Direct
2021-05-25	Common Stock	M	14067	$28.33	Acquired	280705	Direct
2021-05-25	Common Stock	S	130604	$39.31	Disposed	150101	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-25	Stock Option (Right to Buy)	$8.03	M	96167	Disposed	2023-02-26	Common Stock (96167.0)	Direct
2021-05-25	Stock Option (Right to Buy)	$19.6	M	16724	Disposed	2024-03-01	Common Stock (16724.0)	Direct
2021-05-25	Stock Option (Right to Buy)	$28.33	M	14067	Disposed	2027-03-02	Common Stock (14067.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$53.17	2028-03-02	Common Stock (38688.0)	38688	Direct

Footnotes

F1: On March 2, 2021, Mr. Shovlin was granted 38,688 stock options. These options vest ratably over the first four anniversary dates of the grant date

F2: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F3: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F4: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date.